Targeting of human interferon antagonists
AssigneesVib Vzw, Universiteit Gent, Centre National De La Recherche Scientifique, Universite De Montpellier, Centre Hospitalier Regional Universitaire De Montpellier
InventorsJan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
Life of this patent
Estimating the term…
Abstract
The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
Claims4
A method for treating cancer comprising providing to a subject in need thereof an effective amount of a composition comprising a fusion protein, the fusion protein consisting of (i) an interferon antagonist, (ii) a variable domain of camelid heavy chain antibody (VHH) or a variable domain of new antigen receptor (VNAR), and (iii) a linker connecting interferon antagonist and the VHH or VNAR, wherein the interferon antagonist is a human IFNα2 comprising an R120E mutation and wherein the VHH or VNAR is directed to CD19, and
- wherein the cancer comprises cells expressing a CD19 cancer marker, wherein the interferon antagonist binds to the IFNα2 receptor but does not induce signaling at the IFNα2 receptor, and
- wherein the method further comprises providing to the subject an oncolytic virus.
Dependencies are inferred from the claim text.